Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients

A Randomized, Open Label, Parallel-group, Non-inferiority, Active-controlled, Phase Ⅳ Study to Evaluate the Efficacy and Safety of Teneligliptin Versus Linagliptin in Type 2 Diabetes Mellitus Patients

To assess the efficacy and safety of Teneligliptin and Linagliptin in the type 2 Diabetes Mellitus patients.

A randomized, open label, parallel-group, non-inferiority, active-controlled, phase IV study

Inclusion Criteria:

• Patients who are 19 years or older on screening
• Patients with type 2 diabetes mellitus
• Patients with 7.0% ≤ HbA1c ≤ 11.0% at the screening visit
• Patients with Fasting Plasma Glucose <15mmol/L(270mg/dL) on screening

Exclusion Criteria:

-